Posts tagged “Biotech & Life Science”

1:44 p.m. today

Siemens, GSK joint venture team for personalized diagnostic drug tests

DNA An HIV/AIDS treatment developed by GlaxoSmithKline is now being studied with Siemens to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.

9:14 a.m. today

Co-founder of CoLucid Pharmaceuticals in Durham dies

CoLucid Dr. James White, a long-time pharmaceutical executive, launched CoLucid in 2005 along with Art Pappas of Pappas Ventures in Durham.

Updated 7:38 a.m. today

Tale of two drug giants: GSK's pipeline full, AstraZeneca's dwindles

Analysis: While AstraZeneca cuts, GSK is putting itself in a position to discover, develop and position for approval of a wider array of potential drug candidates. It's a strategy that should pay off in the best of times, and the worst of times.

Drug research Drug research

Updated 12:41 p.m. yesterday

GSK is back in the black but reason to cheer?

Chief Executive Officer Andrew Witty used the quarterly performance to tout his performance as CEO and multiple advances in the drug giant's product pipeline. However, two analysts are cautious about the news.

GSK Headquarters    GSK Headquarters

Updated 12:31 p.m. yesterday

Salix drug receives priority FDA review, but partner wants it back

Salix The Raleigh firm is tied up in a law suit over the development of the drug that's intended to help AIDS patients suffering with diarrhea.

9:55 a.m. yesterday

GSK state of the company 2012: From headwinds to tailwinds, says CEO

Andrew Witty, in his fourth year as chief executive officer at GlaxoSmithKline, provides a state of the company overview as GSK reports a return to profitability in the fourth quarter. "For us the headwinds that we've faced for the last four or five years are diminishing, and we've been building more of our own tailwinds in terms of our R&D portfolio and the investment we've been making in our new growth business like emerging markets, consumer, the vaccine business," he says. Witty is also especially excited about progress in R&D.

Andrew Witty Andrew Witty

Updated 9:26 a.m. yesterday

ChannelAdvisor ecommerce webinar; Precision BioSciences patents; Sales Performance to China; Argos drug update

Tech briefs Local tech briefs: ChannelAdvisor to host ecommerce webinar; Precision secures two more patents; Charlotte-based SPI expands to China; Argos touts drug progress.

6:19 a.m. yesterday

Startup Chimerix reports positive test news for transplant drug

Chimerix The company is studying the compound for the prevention of cytomegalovirus diseases, or CMV, in patients who have had stem cell transplants.

1:47 p.m. Monday

GSK puts four clinical trials on hold, development partner says

GSK Anacor Pharmaceuticals discloses that GlaxoSmithKline "voluntarily passed" enrollment in the trials due to a "recently identified microbiological finding" in some patients.

12:33 p.m. Monday

Raleigh-based BioDelivery Sciences gears to raise $40M

BDSI The Raleigh-based specialty pharmaceutical company has filed a shelf registration that would allow BDSI to raise up to $40 million by selling stock if it needs the money.

11:14 a.m. Monday

UNC Nutrition Research Institute lands $1M endowment

Nutrition Institute The gift will create the NRI's first endowed distinguished professorship, The Dickson Foundation-Harris Teeter Distinguished Professorship in Nutrition. Once fully endowed, this professorship will generate an annual disbursement to support a designated Nutrition Research Institute faculty member and foster scientific discovery.

Updated 7:59 a.m. Monday

Lower IPO forces changes in CH-based Cempra drug trial plans

When Cempra initially filed to go public last October, the company said proceeds from the offering would finance four phase 3 clinical trials. But with the smaller stock offering, Cempra needs to scale back those plans.

Cemrpa's product lineup, progress Cemrpa's product lineup, progress

6:58 a.m. Monday

Big pharma could help FDA improve communications

FDA Opinion: The Food and Drug Administration doesn't achieve the impact it's looking for in communications with physicians. The private sector could help.

Updated 6:35 a.m. Monday

Life science news in review: MedCity News headlines

Genome A look back at headlines from MedCity news for the week of Jan. 30-Feb. 5: